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Abstract Purpose: To establish
the relationship between plasma lev-
els of thioredoxin (Trx) and
macrophage migration inhibitory
factor (MIF) in systemic inflamma-
tory stress syndrome (SIRS)/sepsis.
Methods: Enzyme-linked immuno-
sorbent assay measurements of Trx,
MIF, IL-6, -8, and -10 and enzyme-
linked fluorescent assay determina-
tion of procalcitonin (PCT) in plasma
from patients with SIRS/sepsis, neu-
tropenic sepsis, healthy volunteers
and pre-oesophagectomy patients.
Results: Thioredoxin was signifi-
cantly higher in SIRS/sepsis patients
[101.3 ng ml-1, interquartile range
(IQR) 68.7–155.6, n = 32] compared
with that in healthy controls
(49.5 ng ml-1, IQR 31.4–71.1,
P \ 0.001, n = 17) or pre-oesophag-
ectomy patients (40.5 ng ml-1, IQR
36.9–63.2, P \ 0.01, n = 7), but was
not raised in neutropenics (n = 5).
MIF levels were also significantly
higher in SIRS/sepsis patients
(12.1 ng ml-1, IQR 9.5–15.5,
n = 35), but not in the neutropenic
group, when compared with healthy
controls (9.3 ng ml-1, IQR 7.3–10.7,
P \ 0.01, n = 20). Trx levels
correlated, positively, with MIF lev-
els and APACHE II scores. Plasma
levels of IL-6, -8 and -10 and PCT
increased significantly in patients
with SIRS/sepsis (P \ 0.001) and
with neutropenic sepsis, but did not
correlate with Trx or MIF levels.
Conclusion: Plasma levels of Trx,
MIF, IL-6, -8, -10 and PCT were
raised in patients with SIRS/sepsis.
Comparisons between mediators
suggest a unique correlation of Trx
with MIF. Moreover, Trx and MIF
differed from cytokines and PCT in
that levels were significantly lower in
patients with neutropenia compared
with the main SIRS/sepsis group. By
contrast, IL-8 and PCT levels were
significantly greater in the neutro-
penic patient group. The link between
MIF and Trx highlighted in this study
has implications for future investiga-
tions into the pathogenesis of SIRS/
sepsis.
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Introduction
Sepsis and its sequelae are the leading causes of death
amongst the critically ill in non-coronary intensive care
units. Currently, treatment for sepsis is largely supportive,
based upon fluid resuscitation and administration of va-
sopressors and antibiotics. The only pharmacotherapy
shown to reduce mortality in sepsis, in a randomised
clinical trial, is activated protein C [1]. A greater under-
standing of the pathophysiology of sepsis/systemic
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inflammatory stress syndrome (SIRS) could help identify
other effective pharmacotherapies. One therapy that has
shown promise in an animal model of sepsis is an anti-
macrophage migration inhibitory factor (MIF) antibody
[2]. MIF is a 12 kDa, pro-inflammatory protein, released
from immune cells and levels are raised in sepsis [3–5].
Identification of a redox motif in MIF similar to that in
thioredoxin (Trx) has led to the re-classification of MIF as
a Trx-like protein [6, 7].
Thioredoxin is a ubiquitous, 12.5 kDa intracellular
thiol protein with a redox active site containing a con-
served Cys-Gly-Pro-Cys which facilitates protein
reduction [8]. Trx is a potent anti-oxidant that modulates
inflammation, cell growth and apoptosis [8]. Released
during inflammation and oxidative stress, Trx is elevated
in many medical/surgical conditions [8]. There are con-
flicting reports of plasma Trx levels in sepsis.
Specifically, we have shown decreased plasma Trx in
children with meningococcal septic shock (MSS), [9]
whilst others demonstrated increased plasma Trx in adults
with severe sepsis [10]. A positive correlation between
serum Trx and MIF levels in inflammatory bowel diseases
(IBD) has been shown [11]. In experimental models of
IBD Trx was anti-inflammatory, suppressing MIF release/
activity [11].
The aim of this study was twofold. First, to determine
plasma levels of Trx and MIF in adult patients during the
acute phase of SIRS/sepsis compared with healthy con-
trols, pre-oesophagectomy patients and a small sub-group
of patients with neutropenic sepsis. Second, to establish
whether plasma levels of Trx and MIF correlate with each
other; or with IL-8, -10 or -6, cytokines implicated in the
pathophysiology of sepsis; with procalcitonin (PCT), a
marker of bacterial infectious disease [12] or finally,
indices of disease severity and organ failure.
Materials and methods
Plasma samples were collected from 35 patients with
confirmed sepsis, or SIRS with a high clinical suspicion
of sepsis, admitted from March 2005 to June 2007 to
either the adult intensive care unit (AICU) of the Royal
Brompton Hospital (RBH; n = 32) or the AICU of the
Royal Marsden Hospital (RHM; n = 3). Patients met the
American College of Chest Physicians/Society of Critical
Care Medicine (ACCP/SCCM) consensus conference
definition for severe sepsis [13]. A small group of patients
with neutropenic sepsis were also recruited from RMH
(n = 4) and RBH (n = 1). All patients were intubated
and mechanically ventilated. Two control groups were
also recruited; healthy volunteers (n = 20; 10 men, 10
women) and patients requiring oesophagectomy for car-
cinoma from the RMH (n = 8; 6 men, 2 women). The
latter group was chosen in order to determine whether
hospital admission and intubation affect Trx and MIF
levels. Approval for collection and analyses of samples
was obtained from the local research ethics committee.
Informed, written consent was obtained from control
patients and assent from relatives for patients with SIRS/
sepsis and neutropenic sepsis.
Blood samples were collected from patients via an
indwelling arterial cannula and from healthy controls via
antecubital venepuncture. Blood from septic patients was
collected into lithium heparin tubes within 24 h of onset
of illness meeting criteria for SIRS/sepsis and from
oesophagectomy patients directly after intubation, 30 min
prior to oesophagectomy. Plasma was separated (1300 g,
4C, 6 min) and stored at -80C. We have shown pre-
viously that Trx levels are stable in stored plasma samples
[14].
Disease severity and organ failure were assessed using
Acute Physiology and Chronic Health Evaluation
(APACHE) II scores and Sequential Organ Failure
Assessment (SOFA) scores and calculated using the worst
physiological and biochemical parameters recorded dur-
ing the 24 h period following study admission. Amongst
intensive care scoring systems, APACHE II scores are
favoured, because of ease of use and inclusion in the
calculation of age, co-morbidity, and other physiological
variables, indeed significantly more than other scoring
systems.
Procalcitonin was measured by enzyme-linked fluo-
rescent assay (Vidas Brahms, bioMe´rieux Marcy
l’Etoile, France) and analysed on a Biomerieux Vidas
analyser. Commercially available sandwich enzyme-
linked immunosorbent assay (ELISA) kits were used to
measure IL-6, -8 (Hycult, Uden, Netherlands), IL-10
(BD Biosciences, Erembodegem, Belgium) MIF (R & D
Systems, Abingdon, UK) and Trx (Redox Biosciences,
Kyoto, Japan) in duplicate samples. As erythrocytes
have high Trx levels relative to the amounts found in
plasma, free haemoglobin was measured with a Hemo-
Cue plasma/Low Hb photometer and Trx concentrations
corrected for release from haemolysed erythrocytes, as
described, previously, by us and others [14, 15]. Highly
haemolysed blood samples (Hb [ 65 mg/dl), from three
healthy volunteers, three sepsis/SIRS patients and one
pre-oesophagectomy patient, were excluded from Trx,
but not other, measurements.
Data were expressed as median values and interquar-
tile ranges (IQR) and analysed using non-parametric
analysis. Comparisons between groups were made using a
two-tailed Mann–Whitney U or Kruskal–Wallis tests and
correlations between variables were assessed using
Spearman analysis. To assess effects of age as a con-
trolling variable on correlations between MIF and Trx
data were log transformed, subjected to partial correlation
analysis, Pearson correlation coefficients calculated with
and without age and values compared. P values of\0.05
were considered significant.
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Results
Patients with SIRS/sepsis (severe sepsis, n = 3; septic
shock, n = 32) and those with neutropenic sepsis fulfill-
ing the criteria for septic shock (n = 5) were recruited.
There was no significant difference in age between patient
groups (Table 1) and the hospitalised control group
[66.3 years (IQR 58–74.7)]. However, the age of the
healthy control group [32.5 years (IQR 28.5–34)] was
significantly less (P \ 0.0001) than that of the patient
groups. Detailed demographic, clinical and microbiolog-
ical information for SIRS/sepsis patients are presented in
Table 1.
Plasma levels of Trx (101.3 ng ml-1, IQR 68.7–
155.6) were significantly higher in patients with SIRS/
sepsis (n = 32) than healthy controls (49.5 ng ml-1, IQR
31.4–71.1, n = 17, P \ 0.001) or pre-oesophagectomy
patients (40.5 ng ml-1, IQR 36.9–63.2, n = 7, P \ 0.01;
Fig. 1a). Plasma levels of MIF were also significantly
higher in patients with SIRS/sepsis (12.1 ng ml-1, IQR
9.5–15.5, n = 35) when compared with healthy controls
(9.3 ng ml-1, IQR 7.3–10.7, n = 20; P \ 0.01; Fig. 1b).
Plasma levels of neither Trx nor MIF correlated signifi-
cantly with age (r = 0.18, P = 0.29; r = -0.05 and
P = 0.77). Trx and MIF levels in patients with SIRS/
sepsis correlated significantly with each other (r = 0.63,
P \ 0.0001; Fig. 1c). The Pearson partial correlation
coefficient of MIF with Trx (r = 0.725, P \ 0.0001) was
not significantly altered when age was a controlling var-
iable (r = 0.725, P \ 0.0001).
The median APACHE II and SOFA scores are shown
in Table 1. There was a positive correlation between
plasma levels of Trx and APACHE II (r = 0.38,
P \ 0.05, Fig. 1d) but not SOFA scores (r = -0.012,
P = 0.95) in the SIRS/sepsis group. By contrast, MIF
levels in patients with SIRS/sepsis did not correlate with
either APACHE II or SOFA (data not shown). There were
no significant differences in Trx or MIF levels between
patients surviving to hospital discharge or non-survivors
(data not shown).
Plasma levels of IL-6, IL-8, IL-10 and PCT were
significantly (P \ 0.001) increased in SIRS/sepsis
patients compared with control groups but did not cor-
relate with either Trx or MIF levels (Table 2). None of the
cytokines or PCT levels correlated with either APACHE
II or SOFA scores (data not shown). However, when
patients were grouped according to SOFA score bands,
PCT levels in the 10–15 score group (5.6 ng ml-1, IQR
0.95–8.2) were significantly greater than the 1–7 score
group (0.58 ng ml-1, IQR 0.16–1.9, P = 0.02) but not the
8–9 score group. Total leukocyte, neutrophil and mono-
cyte cell counts were also measured in SIRS/sepsis
patients (Table 1) but did not correlate with Trx levels
(r = -0.13, -0.15, -3, respectively) or MIF levels
(r = -0.12, -0.2, -0.12, respectively).
A small group of patients with neutropenic sepsis was
recruited in order to assess the extent to which neutro-
penia during sepsis impacted on levels of Trx and MIF
and for comparison cytokines and PCT. Demographic,
clinical and microbiological information for patients with
neutropenic sepsis are presented in Table 1. All patients
had received recent chemotherapy to treat haematological
cancers. There was no significant difference in IL-10 and
IL-6 levels between neutropenic and non-neutropenic
septic patients (Table 2). However, IL-8 and PCT levels
were significantly (P \ 0.01 and P \ 0.05, respectively)
greater in neutropenics compared with the SIRS/sepsis
group (Table 2). By contrast, in neutropenic patients
levels of Trx (47.4 ng ml-1, IQR 41.6–73.7) and MIF
Table 1 Characteristics of patients with SIRS/sepsis and neutro-
penic sepsis
SIRS/sepsis Neutropenic
sepsis
Age (years)a 64.4 (46.8–75) 60.8 (57.6–61.5)
Gender M/F 22/13 2/3
APACHE II scorea 19 (15–23) 23.4 (20.5–26.5)
SOFAa 9 (8–10) 12 (9–12.5)
Survival to hospital discharge 25 (71.4%) 3 (60%)
Primary cause of admission
Medical 12 5
Cardiac 5 0
Respiratory 5 4
Other 2 1
Surgical 23 0
Cardiac 16 –
Thoracic 5 –
Other 2 –
Sepsis on admission 13 3
Co morbidities
Chronic pulmonary disease 17% 40%
Ischaemic heart disease 46% –
Diabetes 23% –
Neoplasm 23% 100%
Renal, liver, other 17% 80%
Body temperature (C)a 37.5 (36.8–
38.5)
38 (37.3–38.7)
Total leukocyte count
(9109)a
13.6 (11–17.8) 0.1 (0.1–1.6)
Neutrophils (9109)a 10.8 (11–17.8) 0 (0–1.6)
Monocytes (9109)a 0.6 (0.3–0.9) 0 (0–0.1)
Source of infection
Lung 20 4
Blood 9 –
Wound 1 –
Line 1 1
Culture negative 3 –
Other 1 –
Microbiological data
Gram negative bacteria 9 2
Gram positive bacteria 7 1
Polybacterial 5 –
Fungi 1 2
Fungi ? bacterial 9 –
Other 4 –
APACHE Acute physiology and chronic health evaluation, SOFA
Sequential Organ Failure Assessment score
a Median and interquartile range
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(8.9 ng ml-1, IQR 5.6–11.9) were significantly lower
(P \ 0.01 and P \ 0.05, respectively) when compared
with levels in SIRS/sepsis patients (Trx, 101.3 ng ml-1,
IQR 68.7–155.6; and MIF, 12.1 ng ml-1, IQR 9.5–15.5).
Discussion
Plasma levels of Trx and MIF were raised in patients with
SIRS/sepsis but not neutropenic sepsis patients. Pre-
oesophagectomy patients showed similar Trx and MIF
plasma levels to healthy controls, suggesting hospital-
ization and/or intubation are unlikely to account for
increased levels seen in SIRS/sepsis. Positive correlations
between plasma Trx and MIF could suggest a linked role
for these mediators in sepsis.
A doubling of plasma Trx in SIRS/sepsis is similar to
the increase we have previously reported in patients with
acute lung injury (ALI) [14] and others have shown in
patients with severe sepsis [10]. By contrast, plasma Trx
levels are lower in children with MSS compared with
healthy controls [9]. Taken together these studies suggest
that either extreme of Trx levels could be detrimental. We
also report a 1.3-fold increase in plasma MIF in patients
with SIRS/sepsis which contrasts previous reports of
threefold increases, albeit with absolute MIF levels
varying from lower than [16, 17], similar to [2, 18] or
Fig. 1 Trx and MIF in SIRS/
sepsis. Concentrations of
thioredoxin (a) and MIF (b) in
plasma from healthy adult
controls (closed circles), pre-
oesophagectomy patients (pre-
oes, crosses), patients with
systemic inflammatory response
syndrome/sepsis (SIRS/sepsis,
inverted triangle). Data
presented as scattergrams with
median values indicated by
horizontal lines; **P \ 0.01,
***P \ 0.001. Highly
haemolysed blood samples were
excluded from Trx analysis.
Positive correlations between
plasma levels of c thioredoxin
and MIF (r = 0.63,
P \ 0.0001); and d thioredoxin
and APACHE II scores
(r = 0.38, P = 0.05), in SIRS/
sepsis patients are also shown
Table 2 Concentrations of IL-6, IL-8, IL-10 and PCT in plasma samples from healthy controls, pre-oesophagectomy patients and adults
with SIRS/sepsis or neutropenic sepsis: median values (interquartile range)
IL-6 (pg ml-1) IL-8 (pg ml-1) IL-10 (pg ml-1) PCT (ng ml-1)
Healthy controls (n = 20) 0 (0–4) 10.5 (7.8–15.6) 0 (0–1.2) 0.5 (0.05–0.05)
Pre-oesophagectomy (n = 8) 0 (0–4) 10.8 (8.9–13.9) 0 (0–1.2) 0.5 (0.05–0.05)
SIRS/sepsis (n = 35) 63.6 (16.5–259.7)** 36.4 (27.6–67.7)** 19.7 (10.5–36.1)** 1.77 (0.69–5.92)**
Neutropenics (n = 5) 1193 (183.4–1687)**, ns 1169 (217.3–1588)**, $$ 26.0 (12.3–314.8)*, ns 8.64 (4.4–63.5)**, $
MIF versus cytokine/PCTa r = - 0.043ns r = 0.22ns r = 0.07ns r = -0.14ns
Trx versus cytokine/PCTa r = 0.004ns r = 0.27ns r = 0.13ns r = -0.11ns
a Spearman non parametric analysis of correlations between cyto-
kines or PCT and Trx or MIF
*p \ 0.01, **p \ 0.001, compared with control groups
$ p \ 0.05, $$p \ 0.01, nsno significant difference, compared with
SIRS/sepsis group
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higher than [19] those reported in the present study.
Differences in ELISA antibodies and assay protocols
could account for differences in absolute MIF levels.
Varying patient populations could explain variations in
fold increases in MIF levels between ours and other
studies. Thus, those recruited to our study were predom-
inantly from a cardiothoracic ICU unit with secondary
sepsis resulting, in the majority of cases, from lung
infections. By contrast, other studies contained greater
numbers of patients with abdominal complications [16,
17]. This may also account for the low PCT levels seen in
the plasma from our patients with severe sepsis and septic
shock. In addition, the survival rate of patients in our
study was generally higher than in others.
Increases in plasma levels of IL-6, -8 and -10 in SIRS/
sepsis were similar to those in previous studies although
lacked correlation, as shown by others, with disease
severity, organ failure or survival [20]. Significantly
higher levels of IL-8 in neutropenic patients compared to
the SIRS/sepsis group also support the findings of others
[21]. Raised levels of uric acid in LPS challenged neu-
tropenic mice triggered cytokine release from tissue
macrophages [22]. A similar mechanism might also
explain raised IL-8 levels in neutropenic septic patients.
With regard to links in SIRS/sepsis between Trx or MIF
with cytokines there is no definite pattern; indeed, there
are reports of positive, negative, or no, correlation in other
studies [23, 24]. In view of these reports, lack of corre-
lation between cytokines and Trx or MIF in the current
study is perhaps unsurprising.
To our knowledge, only one previous study in patients
with IBD has investigated the relationship between Trx
and MIF and shown a positive correlation [11]. The
correlation in the present study (r = 0.63, P \ 0.0001)
suggests a robust link between variables. Moreover, it is
comparable with the correlation we have identified
between Trx and MIF in post-oesophagectomy patients
(r = 0.86, P = 0.02; n = 7; Leaver et al., unpublished),
further confirming a strong link between these variables.
Reduced sera and colonic tissue MIF was reported in Trx-
transgenic mice and human monocytes treated with hrTrx
released less MIF, indicative of anti-inflammatory effects
of Trx on MIF [11]. Inter-dependent regulation of intra-
cellular Trx and MIF impacting on functions such as
apoptosis has also been reported [25, 26]. By contrast, the
correlation between Trx and APACHE II was weak
(r = 0.38) though statistically significant. We have pre-
viously failed to show correlation between Trx levels and
APACHE II or SOFA scores [14]. In both current and
previous studies the necessity of adapting the calculation
of the scores to within 24 h of admission to the study
might explain weaker correlation.
A concomitant decrease in Trx and MIF in patients
with neutropenic sepsis suffering from malignancy further
supports the idea that these mediators might be linked.
Increased MIF and Trx levels might be predicted in
neutropenic oncology patients given that raised plasma
Trx and MIF levels are associated with cancer [27, 28].
Severely reduced leukocytes numbers could explain
decreased Trx and MIF levels detected in neutropenic
patients. However, no correlation was found between Trx
and MIF with leukocyte cell counts. Alternatively, lower
levels of oxidative stress in neutropenic patients [29]
might explain the differences.
This seemingly tight connection between Trx and MIF
levels in patients with sepsis represents an area for further
research and possible target for therapeutic manipulation.
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